RBC Capital lowered the firm’s price target on Inspire Medical (INSP) to $45 from $56 and keeps a Sector Perform rating on the shares. The company lowered its 2026 revenue guidance to a decline of 4% to 10% from growth of 4% to 10% due to accelerated Inspire 5 coding headwinds, the analyst tells investors in a research note. This, along with the implementation of the WISeR program and modest GLP-1 headwind, will negatively impact Inspire procedure throughout 2026, with potential for some stability into 2027, the firm added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target lowered to $55 from $70 at Mizuho
- Inspire Medical price target lowered to $65 from $70 at Stifel
- Piper downgrades Inspire Medical to Neutral on guidance cut
- Inspire Medical price target lowered to $50 from $63 at Baird
- Inspire Medical downgraded at BofA on cloudy path back to growth